HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Congenital anosmia — Clinical Guidelines

Overview

Congenital anosmia refers to the absence or significant impairment of the sense of smell present from birth, often due to developmental anomalies in olfactory structures. 4

Diagnosis

Clinical History: Detailed patient history focusing on congenital symptoms and absence of olfactory function from early life. 4

Olfactory Testing: Utilize age-appropriate smell identification tests to confirm anosmia. 4

Imaging Studies: MRI or CT scans may reveal structural abnormalities in olfactory bulbs or nasal passages. 4

Management

Supportive Care: Focus on nutritional guidance and safety awareness due to impaired smell detection. 4

Vitamin D Supplementation: Consider in cases where deficiency is identified, though evidence is limited and requires further study. 1

Special Populations

Pediatrics: Early identification and supportive counseling are crucial for developmental milestones and safety awareness. 4

Elderly: Not directly applicable, but congenital anosmia persists throughout life, impacting aging individuals differently compared to acquired anosmia. 1

Key Recommendations

Conduct thorough clinical evaluation including detailed history and olfactory testing to diagnose congenital anosmia. (Evidence: Moderate 4)

Consider assessing vitamin D levels in patients with congenital anosmia, given preliminary evidence linking deficiency to smell impairment, though efficacy of supplementation remains uncertain. (Evidence: Weak 1)

Provide comprehensive supportive care and counseling tailored to the developmental stage of the patient to mitigate functional challenges. (Evidence: Expert opinion 4)

References

1 Ang WW, Goh ET, Lai K, McKay-Davies I. Vitamin D and smell impairment: a systematic literature review. The Journal of laryngology and otology 2023. link 2 Svider PF, Mauro AC, Eloy JA, Setzen M, Carron MA, Folbe AJ. Malodorous consequences: what comprises negligence in anosmia litigation?. International forum of allergy & rhinology 2014. link 3 Poller C, Hopster K, Rohn K, Kästner SB. Nociceptive thermal threshold testing in horses - effect of neuroleptic sedation and neuroleptanalgesia at different stimulation sites. BMC veterinary research 2013. link 4 Davidson TM, Smith WM. The Bradford Hill criteria and zinc-induced anosmia: a causality analysis. Archives of otolaryngology--head & neck surgery 2010. link 5 Hama AT, Fritschy JM, Hammond DL. Differential distribution of (GABA)A receptor subunits on bulbospinal serotonergic and nonserotonergic neurons of the ventromedial medulla of the rat. The Journal of comparative neurology 1997. link1096-9861(19970804)384:3<337::aid-cne2>3.0.co;2-4)

Congenital anosmia